Combination Therapy For Type 2 Diabetes With Rosiglitazone (RECORD Study) Shows No Increase Of Cardiovascular Disease Or Death

June 6, 2009

The results of the RECORD study are reported in an article published Online First and in a future edition of The Lancet. The findings are presented at the same time at the American Diabetes Association (ADA) meeting in New Orleans, USA. They indicate that the use of rosiglitazone (Avandia) together with regular diabetes treatments (metformin or a sulfonylurea) to reduce blood glucose in type 2 diabetics does not raise the risk of cardiovascular disease or death. On the other hand, the research establishes that using rosiglitazone multiplies by more than two the risk of heart failure, and increases the risk of fracture, mostly in women.
Read the rest of this entry »


Combination Therapy For Type 2 Diabetes With Rosiglitazone (RECORD Study) Shows No Increase Of Cardiovascular Disease Or Death

June 6, 2009

The results of the RECORD study are reported in an article published Online First and in a future edition of The Lancet. The findings are presented at the same time at the American Diabetes Association (ADA) meeting in New Orleans, USA. They indicate that the use of rosiglitazone (Avandia) together with regular diabetes treatments (metformin or a sulfonylurea) to reduce blood glucose in type 2 diabetics does not raise the risk of cardiovascular disease or death. On the other hand, the research establishes that using rosiglitazone multiplies by more than two the risk of heart failure, and increases the risk of fracture, mostly in women.
Read the rest of this entry »


In Trastuzumab-Resistant Metastatic Breast Cancer, Small Molecule Inhibitor Shows Promise

May 30, 2009

Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy.

“I think this is very promising. Neratinib induces clinically meaningful responses,” says Ramona Swaby, M.D., a medical oncologist and attending physician at Fox Chase. Swaby will present the study results on Monday, June 1, at the annual meeting of the American Society of Clinical Oncology.
Read the rest of this entry »


In Biliary Cancer Study Targeted Agent Shows Promise

April 22, 2009

An experimental agent has shown promising results in people with advanced biliary cancer, according to a multi-institutional clinical trial led by cancer researchers at the Ohio State University.

The agent, known as AZD6244 (ARRY-142886), blocks certain enzymes that cancer cells need to proliferate and survive.

About 100,000 patients are diagnosed with biliary cancer worldwide every year, representing 15-20 percent of all liver cancer cases. Most patients present at later stages of the disease, which has a universally poor outcome.
Read the rest of this entry »


XMT-1107, Shows Superior Pharmacokinetics And Anti-Tumor Activity

April 21, 2009

  Mersana, a platform-based cancer therapeutics company, announced positive results of preclinical studies for its second development candidate, XMT-1107, in two posters at the 2009 Annual Meeting of the American Association of Cancer Research (AACR) in Denver.

The studies showed that XMT-1107, a novel anti-angiogenic fumagillin analog conjugated to Mersana’s proprietary Fleximer(R), demonstrated superior anti-tumor activity in tumor xenograft models in comparison to other anti-angiogenic agents and extended exposure to the conjugated drug, supporting the potential clinical utility of XMT-1107 as an anti-cancer agent. Full text of the abstracts can be viewed online at the AACR website at http://www.AACR.org.
Read the rest of this entry »


Nab-Paclitaxel Added To Gemcitabine And Epirubicin Shows Potential As Neoadjuvant Treatment For Early Breast Cancer

January 15, 2009

SAN ANTONIO – NabTM-paclitaxel (Abraxane), used in tandem with gemcitabine and epirubicin, is showing good anti-tumor activity and tolerability as neoadjuvant treatment for women with locally advanced breast cancer, according to phase II results released at the 2008 San Antonio Breast Cancer Symposium (SABCS).

Nab-paclitaxel is a novel albumin-bound paclitaxel, an established chemotherapy agent, combined with albumin, a very small naturally-occurring protein.
Read the rest of this entry »


Secure Fixation After EVAR In Patients With Wide Aortic Necks: A Safe And Effective Alternative To Open Surgery In Many Patients, Trial Shows

January 11, 2009

Recanalization of infrapopliteal arteries is important in patients with chronic limb ischemia to decrease limb-loss.

Dr. Konstantinos Katsanos, of the Department of Radiology, Patras University Hospital School of Medicine, Patras, Greece, reviewed published data that highlighted the promising long-term limb salvage rates of below-the-knee angioplasty. But, he noted re-occlusion following infrapopliteal angioplasty and stenting is identified in more than 50% of cases by 1 year thereby resulting in a high frequency of repeat procedures. Drug-eluting stents (DES) have emerged as a potential solution to prevent restenosis from occurring.
Read the rest of this entry »